3-Isobutyl-1,2,5,6,7,7a-hexahydro-3H-pyrrolizin | 91369-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚里西啶
• 英文名称: 3-Isobutyl-1,2,5,6,7,7a-hexahydro-3H-pyrrolizin
• 英文别名: 3-isobutyl-hexahydro-pyrrolizine；3-(2-methylpropyl)-2,3,5,6,7,8-hexahydro-1H-pyrrolizine
• CAS: 91369-85-6
• 化学式: C₁₁H₂₁N
• 分子量: 167.294
• InChiKey: CKYWIPYCZQBPGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221167B2

  公开（公告）日：2019-03-05

  Disclosed are compounds of Formula A, or a salt thereof: wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.

  公开了式 A 的化合物或其盐： 其中 R1、R2 和 E 在此定义，这些化合物具有抑制外周神经元和交感神经元中 Nav 1.7 离子通道的特性。还描述了包含式 A 化合物或其盐类的药物制剂，以及用其治疗疼痛疾病、咳嗽和瘙痒的方法。
• Aminopyrazine compounds with A2A antagonist properties
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10472347B2

  公开（公告）日：2019-11-12

  Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein “R1”, “RA-1”, “R2”, “R3”, and “Het” are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

  公开了式A和式A-1化合物或其盐，以及包含这些化合物或其盐的药物制剂（药物组合物）；其中 "R1"、"RA-1"、"R2"、"R3 "和 "Het "如上文所定义，这些化合物被认为适用于选择性拮抗A2a受体，例如，在基底神经节中高密度存在的A2a受体。 此类化合物和药物制剂被认为可用于治疗或控制神经退行性疾病，例如帕金森病，或因使用某些用于治疗或控制帕金森病的药物而引起的运动障碍。
• HYDROXYALKYLAMINE- and HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170174674A1

  公开（公告）日：2017-06-22

  Disclosed are compounds of Formula A, or a salt thereof: wherein R 1 , R 2 , and E are defined herein, which compounds have properties for inhibiting Na v 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same.